Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer – a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

This publication has 22 references indexed in Scilit:

• Paclitaxel and Cisplatin Combination Chemotherapy in Recurrent Epithelial Ovarian Cancer
  Gynecologic Oncology, 1996
• Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel
  Gynecologic Oncology, 1996
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients
  JNCI Journal of the National Cancer Institute, 1994
• Salvage Carboplatin Therapy for Advanced Ovarian Cancer After First-Line Treatment with Cisplatin
  American Journal of Clinical Oncology, 1992
• Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy
  European Journal of Cancer and Clinical Oncology, 1991
• The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing
  International Journal of Gynecologic Cancer, 1991
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
  Gynecologic Oncology, 1990
• Cisplatin Plus VP16 213 in Refractory Ovarian Carcinoma
  American Journal of Clinical Oncology, 1987
• Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent
  Gynecologic Oncology, 1985